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Background: Gardnerella vaginalis is identified as the predominant colonist of the vaginal tracts of women
diagnosed with bacterial vaginosis (BV). G. vaginalis can be isolated from healthy women, and an asymptomatic BV
state is also recognised. The association of G. vaginalis with different clinical phenotypes could be explained by
different cytotoxicity of the strains, presumably based on disparate gene content. The contribution of horizontal
gene transfer to shaping the genomes of G. vaginalis is acknowledged. The CRISPR loci of the recently discovered
CRISPR/Cas microbial defence system provide a historical view of the exposure of prokaryotes to a variety of foreign
genetic elements.
Results: The CRISPR/Cas loci were analysed using available sequence data from three G. vaginalis complete
genomes and 18 G. vaginalis draft genomes in the NCBI database, as well as PCR amplicons of the genomic DNA of
17 clinical isolates. The cas genes in the CRISPR/Cas loci of G. vaginalis belong to the E. coli subtype. Approximately
20% of the spacers had matches in the GenBank database. Sequence analysis of the CRISPR arrays revealed that
nearly half of the spacers matched G. vaginalis chromosomal sequences. The spacers that matched G. vaginalis
chromosomal sequences were determined to not be self-targeting and were presumably neither constituents of
mobile-element-associated genes nor derived from plasmids/viruses. The protospacers targeted by these spacers
displayed conserved protospacer-adjacent motifs.
Conclusions: The CRISPR/Cas system has been identified in about one half of the analysed G. vaginalis strains. Our
analysis of CRISPR sequences did not reveal a potential link between their presence and the virulence of the
G. vaginalis strains. Based on the origins of the spacers found in the G. vaginalis CRISPR arrays, we hypothesise that
the transfer of genetic material among G. vaginalis strains could be regulated by the CRISPR/Cas mechanism. The
present study is the first attempt to determine and analyse the CRISPR loci of bacteria isolated from the human
vaginal tract.
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Gardnerella vaginalis, a facultatively anaerobic bacterium
of the Bifidobacteriaceae family, is strongly associated
with bacterial vaginosis (BV): a disease characterised by
malodorous vaginal discharge [1-3]. Women with BV are
at risk of poor reproductive health outcomes and the ac-
quisition of some sexually transmitted diseases [2,4]. BV is
defined as a shift in microbial species from hydrogen
peroxide producing Lactobacillus to anaerobic bacteria
including G. vaginalis, Atopobium vaginae, Prevotella,
Peptostreptococcus, and Bacteroides spp. [5,6]. The gold* Correspondence: mildap@ibt.lt
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distribution, and reproduction in any mediumstandard for laboratory diagnosis of BV is the Gram stain,
which is used to determine the relative concentrations of
lactobacilli and the bacteria characteristic of BV [7]. The
state of asymptomatic BV has also been recognised, al-
though Gram stains revealed a decrease in lactobacilli and
an increase in the abundance of anaerobes specific to BV
[8]. The same G. vaginalis that is recovered as the prevail-
ing inhabitant of the vaginal tracts of women diagnosed
with BV is also found in BV-negative women, though at
much lower numbers [5,9,10]. The issue of G. vaginalis
commensalism is still unclear, as the vaginal bacterial
community is dynamic and tends to change during the
menstrual cycle to produce transient dominance of
G. vaginalis in healthy women [11,12]. Using culture-tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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vaginal microbiota may differ among human populations:
Hispanic and non-Hispanic black women have signifi-
cantly more anaerobes and fewer lactobacilli than Asian
and Caucasian women [12]. Thus, low counts of Lactoba-
cillus do not necessarily indicate the BV state [6,13].
The association of G. vaginalis with different clinical
phenotypes could be explained by different cytotoxicity of
the strains, presumably based on disparities in their gene
content. Until recently, surprisingly little has been known
about the genetics of G. vaginalis. In 2010, the genomes of
several G. vaginalis strains from the vaginas of BV and
non-BV patients were sequenced, providing information
about the bacterium and enabling comparative genomic
analyses [14,15]. Attempts have also been made to expand
the knowledge of the genotypic and phenotypic diversity
of G. vaginalis strains in terms of virulence factors: par-
ticularly vaginolysin, sialidase, and biofilm-forming
proteins [16-18]. The development of methods for the
genotypic differentiation of G. vaginalis revealed that the
genomes exhibit great variability. Therefore, some conven-
tional methods, including pulse field gel electrophoresis,
restriction fragment length polymorphism, classical ribo-
typing with Southern blot, and restriction enzyme analysis,
are not applicable for typing this species [19-21]. The
amplified ribosomal DNA restriction analysis method,
while applicable to the genotypic differentiation of
G. vaginalis, has been found to not be discriminatory
enough for pathogenetic and epidemiological studies
of G. vaginalis [17,18].
Recent data from G. vaginalis comparative genomic
analyses have indicated that the bacterium possesses a
small core genome, consisting of 746 genes, that accounts
for only 27% of the pan-genome of the species [22]. The
small number of unique genes (21) in the individual
strains of G. vaginalis and the genomic plasticity among
the strains suggest that horizontal gene transfer (HGT) is
active; but there is frequent homologous recombination
among G. vaginalis strains, as well as the intake of foreign
DNA from other species [15,22].
Clustered Regularly Interspaced Short Palindromic
Repeats (CRISPRs) and their associated cas genes consti-
tute a bacterial and archaeal defence mechanism against
exogenous nucleic acids [23]. The majority of archaea
and approximately half of bacterial genomes contain
CRISPR loci [24]. CRISPR loci consist of unique sequences
(spacers) that intercalate between short conserved repeat
sequences. The spacer sequences often originate from
invading viruses and plasmids [25,26]. The CRISPR/Cas
defence mechanism relies on RNA interference that pre-
vents bacteriophage infection and plasmid conjugation,
thus restricting two routes of HGT [27]. Analyses of
CRISPR sequences have been used in a variety of applica-
tions including strain genotyping and epidemiologicalstudy, detection of evolutionary events and bottlenecks,
investigation of the history of virus exposure, and host
population dynamics, providing insights into the domin-
ant routes of HGT [28-32]. The current study targeted the
detection and analysis of CRISPR loci in the genomes of
17G. vaginalis strains isolated from the vaginal tracts of
women diagnosed with BV [18], and also in the genomes
of 21G. vaginalis strains deposited in the NCBI genome
database.
In the current study, we examined the origins of
CRISPR spacers representing the immunological mem-
ory of G. vaginalis strains, and we hypothesised about
the impact of CRISPR/Cas on the emergence of genetic
variability of G. vaginalis strains. Also, we demonstrated
the restricted distribution of the CRISPR loci among the
G. vaginalis strains.Methods
G. vaginalis strains
Seventeen G. vaginalis strains isolated from clinical speci-
mens obtained from the vaginal tracts of women diag-
nosed with BV were used in this study [18]. The isolates
had been previously genotyped/biotyped and characterised
with respect to the main known virulence factors, namely
vaginolysin and sialidase [18].
Three completely sequenced G. vaginalis genomes
(ATCC14019, CP002104.1; 409–05, CP001849.1; and
HMP9231, CP002725.1) and 18 G. vaginalis draft gen-
omes were retrieved from the NCBI genome database
(http://www.ncbi.nlm.nih.gov/genome/genomes/1967).
The accession numbers of the draft genomes are listed
in Additional file 1.CRISPR amplification and sequencing
Primers for CRISPR amplification were designed by
genomic comparison of the CRISPR flanking regions of
G. vaginalis strains ATCC 14019, 5–1, AMD, 409–05,
41V, 101, and 315A. Three different sets of primers;
Cas-1-1fw, Cas-3-1fw, CR-1rev, CR-2rev and CR-3rev;
were used for the amplification of the CRISPR regions
(Additional file 2). PCR was performed in a 50-μl reaction
mixture containing 0.2 μM each primer, 20 ng genomic
DNA and 1.5 U Long PCR Enzyme Mix (Thermo Scien-
tific Fermentas, Vilnius, Lithuania). The reaction mixture
was subjected to 28 cycles of denaturation at 94°C for
30 s, primer annealing at 50°C for 40 s, and extension at
72°C for 3 min. The final extension step was prolonged to
10 min. PCR products were purified using GeneJET Gel
Extraction Kit (Thermo Scientific Fermentas) according to
the manufacturer‘s instructions. The cloned DNA frag-
ments were subjected to sequencing using the ABI
3130XL genetic analyser. Sequence walking was explored
using internal primers constructed within the spacer
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fragments.
A slightly modified spacer-crawling approach [29] was
applied to amplify the CRISPR arrays of strains GV28 and
GV33. The primers targeted cas2 and the repeat sequence
within the CRISPR locus. The resulting PCR product
represented a ladder consisting of a number of fragments
with increasing lengths: each fragment differed by the
length of one spacer and one repeat. The mixture of frag-
ments was cloned into the pJET1.2 vector (Thermo Scien-
tific Fermentas); the recombinant plasmids containing the
longest DNA inserts were selected and then subjected to
sequencing. The next round of amplification used the pri-
mer generated from the further spacer sequence and the
primers located on the flanking regions downstream of
the CRISPR sequence (Additional file 2). The resulting
contigs were assembled with a minimum overlapping re-
gion of three spacers.
Amplification and sequencing of the cas genes
The presence of the cas genes was verified by amplifica-
tion of the regions containing cas5-cas6e-cas1-cas2
(~3.6 kbp), cas3-cse1 (~3 kbp), cse2-cas5 (~2.7 kbp),
cas5 (~0.88 kbp) and cse2 (~0.6 kbp). The primers used
in the PCR are provided in Additional file 2. The PCR
regimen included 28 cycles of denaturation at 94°C for
30 s, primer annealing at 58°C for 30 s, and extension at
72°C for 1 min/kb PCR target. The final extension step
was prolonged to 10 min. The cloned DNA fragments
containing cas5 and cas2 were subjected to sequencing.
CRISPR sequence analysis
CRISPR information for the three G. vaginalis genomes
(ATCC14019, 409–05, and HMP9231) was retrieved
from the CRISPR database [24]. CRISPRs Finder [24]
was used to detect CRISPR repeat and spacer sequences.
The identification of cas genes was also performed using
NCBI BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Each piece of CRISPR and cas information retrieved
from the databases was manually proofread. The search
for similarities between each spacer and the sequences
deposited in GenBank was performed using BLASTn at
NCBI, with the search set limited to Bacteria (taxid:2) or
Viruses (taxid:10239). All matches with a bit score above
40.0, corresponding to 100% identity over at least 20 bp,
were considered legitimate hits. Only the top hit was
taken into consideration. Matches to sequences found
within G. vaginalis CRISPR loci were discarded. Spacers
were compared to one another using the MAFFT pro-
gram [33]. CRISPR spacers with up to three mismatches
that had 100% overlap between sequences were consid-
ered identical. The consensus sequences of the CRISPR
repeat and protospacer region alignments were gener-
ated by WebLogo [34].Results
Architecture of CRISPR/Cas loci in G. vaginalis strains
Two of the three completely sequenced G. vaginalis
genomes, 12 of the 18 draft genomes in GenBank, and 6
of the 17G. vaginalis clinical isolates contained a cas
gene cluster and a CRISPR locus. Sequences consisting
of repeats/spacers adjacent to the cas genes were consid-
ered CRISPR sequences. The CRISPR/Cas loci in the
majority of strains were located between the core gene
clpC and the gene encoding tRNAGly (Figure 1).
The region between the 30-end of clpC and the cas
genes had ORFs encoding hypothetical proteins and was
variable in length (~5-19 kbp), depending on the strain.
The region between the 30-end of the CRISPR array and
the gene encoding tRNACys was not conserved among
G. vaginalis strains and varied in length (0.4-1.8 kbp)
from strain to strain. The CRISPR/Cas loci of strains
409–05, 00703B, and 00703C2 had different flanking
sequences surrounding them. Notably, the region down-
stream of the CRISPR arrays found in clinical isolates
GV21, GV30, GV22, and GV25 corresponded to that
found in the genome of the ATCC14019 strain; while
the CRISPR flanking sequences on the right, determined
in the GV28 and GV33 strains, did not show any simi-
larity to the sequences detected downstream of the
G. vaginalis CRISPRs. Due to the variability of the flank-
ing sequences downstream of the CRISPR locus and
long CRISPR amplicon, strains GV28 and GV30 con-
tained cas genes but did not produce PCR products. The
CRISPR sequences in those two strains were identified
using the spacer-crawling approach described in the
Methods section. The sequences of the amplified CRISPR
regions of six G. vaginalis strains analysed in this study
were deposited to GenBank database under the Accession
numbers JX215337-JX215342.
The cas loci of G. vaginalis consisted of the cas genes
cas3-cse1-cse2-cse4-cas5-cas6e-cas1-cas2. The detected
gene cluster belongs to type I, subtype I-E, known as
Ecoli [35]. CRISPR loci were located downstream of cas2
and contained from 1 to 50 spacer sequences. Amplifica-
tion of the regions containing different cas genes was
performed to eliminate false-negative PCRs for CRISPR
sequences. PCR products consisting of different sets of
cas genes (cas5-cas6e-cas1-cas2, cas3-cse1, cse2-cas5,
cas5, and cas2) were obtained from clinical isolates iden-
tified as being PCR-positive for CRISPR sequences. The
sequences of cas2 and cas5 were subjected to sequen-
cing, and their sequences were deposited in GenBank
under the Accession numbers JX215343-JX215345.
Characterisation of CRISPR repeat and spacer sequences
The repeat sequence found in the CRISPR loci of the 20
G. vaginalis strains consisted of 28 bp (Figure 2A), while
the spacers in the loci varied in size from 33 to 34 bp.
Figure 1 Position of CRISPR/Cas locus on the chromosome of G. vaginalis. The flanking sequence region shared by several strains
downstream of the CRISPR array is marked by vertical dashed lines.
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the proximal ends of the CRISPR repeat (Figure 2A).
The repeat sequence of CRISPR was partially palin-
dromic and forms a putative RNA secondary structure
with ΔG < − 10 kcal/mol (Figure 2B).
The CRISPR arrays found in the G. vaginalis strains var-
ied in length and spacer content: the longest CRISPR locus
contained 40 unique spacers (40/50) and was detected in
clinical isolate GV25, while only one spacer adjacent to
the cas genes was found in strain 1400E. Across six clinical
isolates of G. vaginalis, 175 spacers were identified; among
them, 129 unique spacers were detected (Figure 3). The
fourteen G. vaginalis genomes deposited in GenBank
carried 81 unique spacers out of the 110 spacer sequences
that were analysed (Figure 3). A total of 285 spacers adja-
cent to the cas genes were identified among the 20
G. vaginalis strains containing CRISPR/Cas loci (Figure 3).
The trailer-end spacers of the CRISPR loci, i.e. the old-
est spacers found farthest from the leader sequencesFigure 2 Features of the repeat in the G. vaginalis CRISPR arrays. (A) S
height of the letters shows the relative frequency of the corresponding nu
repeat region predicted using RNAfold [36].[37], exhibited several types of conservation: nine strains
of G. vaginalis shared one spacer, five strains (among
them, the three clinical isolates GV22, GV25, and GV30)
shared two spacers, whereas three strains (GV28,
00703B and 00703C2) contained distinct spacer se-
quence conservation at the trailer -end (Figure 3). All
spacer sequences detected within the CRISPR locus of
G. vaginalis strain 315A had a copy at the trailer-end of
clinical isolate GV22 (Figure 3).
Analysis of CRISPR spacer sequences
All 210 unique spacer sequences were blasted against
phage, plasmid, and bacterial sequences. It has been sug-
gested that 100% identity between spacer and protospa-
cer sequences is required to provide CRISPR-mediated
immunity [38]; while the tolerance for mismatches is not
yet completely elucidated [39,40]. Therefore, a search for
protospacers was performed, exploring a less stringent
identity criterion by setting a cut-off described in theequence logo for all repeats in the CRISPR loci of G. vaginalis. The
cleotide at that position. (B) Secondary structure of the G. vaginalis
Figure 3 Graphic representation of CRISPR spacers in G. vaginalis clinical isolates (A) and G. vaginalis genomes deposited in GenBank
(B). Spacers are represented by boxes; repeats are not included. The leader-end spacers are oriented on the left of each array; the trailer-end
spacers are oriented on the right side of each array. Identical spacers are represented by the same number and colour. Unique spacers are white-
coloured. Spacers with mismatches of up to three nucleotides (see Methods) are indicated by dots on the top of the spacer. The number of dots
shows the number of mismatched nucleotides.
Figure 4 Matches of CRISPR spacers identified in G. vaginalis
strains to plasmid, bacteriophage, and chromosomal
sequences, expressed in percentages.
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match to the GenBank database (Figure 4). Overall,
among the 70 spacers with matches to the selected cut-
off, one sequence showed similarity to a viral sequence,
one sequence matched a plasmid sequence, and 68
sequences (97%) showed similarity to chromosomal
sequences (Figure 4; Additional file 3). Among the
CRISPR spacers matched to chromosomal sequences of
non-G.vaginalis origin, five of 77 spacers were similar to
sequences originating from human-associated bacteria
including Haemophilus influenza, Weeksella virosa,
Campylobacter jejuni, and Bacillus cereus (Additional
file 3B). Nearly half of the spacers (32 of 77) were similar
to G. vaginalis chromosomal sequences, including 10
spacers that shared 100% identity (33 of 33 nucleotides;
Additional file 3A). All of these spacers, almost uni-
formly distributed throughout the CRISPR arrays, were
unique sequences except for spacer #106 located at the
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and GV25.
Spacers matching G. vaginalis chromosomal sequences
The 28 spacers had significant nucleotide matches to
G. vaginalis chromosomal regions (85 to 100% identity),
except for three spacers in the CRISPR array of strain
00703B and one spacer found in strain GV22 displaying
up to 77% identity (Additional file 3A). Few spacers shared
identity with the sequences annotated as having phage ori-
gin. Analysis of the G. vaginalis genomes revealed the ex-
istence of four to seven phage-associated genes, though
most of those were present in one strain and absent in the
other strains [15]. We were not able to determine whether
the clinical isolates contained the sequences of phage ori-
gin targeted by the spacers, because the complete genome
sequences are not available yet.
A majority of the spacer hits that mapped to the
sequences did not associate with mobile elements
(Additional file 3A). The protospacers are localised on
both strands of the G. vaginalis chromosome, covering
coding and non-coding regions. A substantial number of
spacers targeting the same region were distributed con-
secutively in the CRISPR arrays. Nearly 60% of the
CRISPR spacers targeted protospacers located on the
chromosome of G. vaginalis strain 409–05 (Additional
file 3A). Moreover, different spacers from the CRISPR
arrays of different strains targeted the same region of the
chromosome. Namely, the spacers in the CRISPR arrays
of strains GV22 (one spacer), GV25 (one spacer), GV28
(one spacer), and GV30 (five spacers) clustered in a
small 1.1 kbp area and matched the same non-coding re-
gion on the chromosome of strain 409–05 (Additional
file 3). We did not identify spacers in the CRISPR array
of strain 409–05 that shared homology with regions of
G. vaginalis chromosomal DNA. Several spacers (#100
and #163) originating from different strains targeted the
gene encoding N-acetylmuramoyl-L-alanine amidase. None
of the CRISPR spacers were found to be self-targeting. We
examined the five genomes of G. vaginalis available in
the NCBI genome database that had spacers targeting cod-
ing and non-coding regions on the chromosomes of
strains 409–05, 6420B, 315A, 41 V, ATCC14019, and
AMD. We did not find a match between the spacers and
the endogenous genomic sequences, except for the
sequences located in the CRISPR arrays.
We also analysed whether the protospacers located on
the G. vaginalis chromosome displayed conserved proto-
spacer adjacent motif (PAM) sequences [41,42]. We
aligned the protospacers with the flanking regions com-
prising 20 bp on both sides. Alignments were performed
for ten protospacers sharing 100% identity with the
spacers. The conserved motif of two nucleotides (AA)
situated immediately upstream of the target region wasdetected (Figure 5). The PAM signature AA was con-
firmed for nine protospacers with up to 10% mismatches
located distant from the 50- and 30-ends of the spacers.
Thus, the motifs adjacent to the protospacers located
in the G. vaginalis genomic DNA bear the signatures
of PAMs. The orientation of the G. vaginalis PAM is
50-AA-protospacer-30, which coincides with the orienta-
tion of the PAM identified in E. coli as CRISPR/Cas;
both bacteria belong to the same type [41,42]. Among all
of the G. vaginalis CRISPR arrays, the first nucleotide of
97.5% of the spacers was either C or T. Only six spacers
started with A or G (2.5%). All of the spacers targeting
the protospacers on the G. vaginalis chromosome
started with C or T (18:13).
Discussion
The CRISPR locus of the recently discovered CRISPR/
Cas defence system in prokaryotes protects against in-
vading viruses and plasmids and is a map of the “im-
munological memory” of the microorganism [25,26].
The spacer sequences that are incorporated into the
CRISPR loci provide a historical view on the exposure of
the bacteria to a variety of foreign genetic elements [23].
A recent report on the ability of CRISPR/Cas to prevent
natural transformation in Streptococcus pneumoniae
enlarged the role of CRISPR in bacterial nucleic acid-
based immunity and the impact that CRISPR has on the
emergence of bacterial pathogens [43].
In the current study, we analysed the CRISPR arrays in
17 recently characterised G. vaginalis clinical isolates [18]
and the genomes of 21 of G. vaginalis strains deposited in
the NCBI genome database. We examined the spacer
repertoire and evaluated the potential impact of CRISPR/
Cas on gene uptake in G. vaginalis.
We found that six clinical isolates (35%) and 14
G. vaginalis genomes deposited in the NCBI database
(67%) contained CRISPR/Cas loci. The loci included
complete cas genes and repeat sequences interspaced by
a variable number of spacers. The repeat sequence in
the CRISPR array of G. vaginalis was not identical to
that found in the E. coli CAS-E subtype [44]. In silico
analysis of the Cas proteins revealed highly conserved
(>97% identity) sequences among the G. vaginalis
strains. The Cas proteins showed the highest similarity
(46 to 63% identity) to the proteins from A. vaginae
DSM15829 (Ecoli Cas subtype); meanwhile, 9 to 35%
identity was scored to the Cas proteins from E. coli K12
strain MG1655, which are attributable to the same sub-
type [35]. The AT-rich leader sequence immediately up-
stream of the first CRISPR repeat was detected in the
genomes of all of the analysed G. vaginalis strains.
Analysis of the spacer repertoire revealed different activ-
ities of the CRISPR/Cas loci across different G. vaginalis
strains. The CRISPR locus identified in the genome of
Figure 5 WebLogo for the PAM consensus sequence determination. Ten protospacers identical to spacers were aligned relative to the 50-
end of the protospacer (base 1). Sequences include the protospacer (positive numbers) and 13 nucleotides (negative numbers) upstream of the
first base of the protospacer (containing the PAM).
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of the degree of spacer polymorphism exhibited by both
the total number of unique spacers and the total number
of unique spacer arrangements [38,45]. In contrast, the
spacer content in the CRISPR array of strain 315A could
indicate that newly gained CRISPR spacers were deleted
and the most ancient spacers were preserved (Figure 3B).
We may assume that cas activity in the genome of
G. vaginalis strain 315A was depleted [37,45].
In the present work, the analysis of CRISPR loci
revealed that the majority of CRISPR spacers were simi-
lar to chromosomal sequences of both G. vaginalis and
non-G.vaginalis origins. Spacer matches to viral and
plasmid sequences suggest their putative origin, because
there is no evidence of plasmids in the G. vaginalis
genomic architecture, and viruses that infect G. vaginalis
are not yet known [15,22]. A substantial portion of the
spacers matched G. vaginalis chromosomal sequences.
The spacers shared identity with coding and non-coding
sequences in the chromosome of G. vaginalis. The spacers
were not self-targeting [46], and the protospacers located
on the chromosome displayed PAMs. The question of
whether C or T is the first base of the spacer or the 29th
base of the repeat in G. vaginalis CRISPR arrays is still
open [46,47]. In our study, all spacers targeting protospa-
cers on the G. vaginalis chromosome started with either C
or T. Thus, the spacers correspond to the AAT-PAM or
AAC-PAM, assuming that the C/T originates from the
repeat. Hypotheses about the borders of the CRISPR
repeats/spacers need experimental testing; however, the
idea of a “duplicon” seems attractive [47].
The analysis of the genomes of G. vaginalis presumed
that the chromosomal sequences targeted by spacers did
not derive from plasmids or viruses and that the genes
in the vicinity of the protospacers (approx. 5 kbp up-
stream and 5 kbp downstream) do not have viral origin.
The gene-coding sequences targeted by the G. vaginalis
CRISPR/Cas system were found to not be constituents
of mobile-element-associated genes such as restriction-
modification and toxin-antitoxin systems or transposases
[45,48]. Two spacers from different strains targeted the
gene encoding N-acetylmuramoyl-L-alanine amidase: aCHAP-family domain protein found to have lytic ability
[49]. Several strains possess spacers matching the gene
encoding the glycoside hydrolase (GH) family 25 protein
and the non-coding regions in its close vicinity. The GH
25 family comprises lysozyme able to hydrolyse peptido-
glycan and two Abi proteins conferring resistance to a
broad range of related bacteriocins [15,50]. It has been
suggested that these findings are in agreement with the
data showing that G. vaginalis strains produce sub-
stances antagonistic to bacterial isolates common to the
vaginal microbiome [15,51]. A substantial part of the
spacers targeted non-coding regions or ORF’s encoding
hypothetical proteins with undefined functions.
Our data suggest that the CRISPR/Cas system was in
touch with G. vaginalis DNA that was most probably of
chromosomal origin and accessed by the transformation,
transduction, or conjugation routes. DNA acquisition and
exchange by natural transformation among G. vaginalis
strains was detected as a favourable route [22]. Moreover,
G. vaginalis strains were found to encode the competence
promoting proteins ComEA, ComEC, and CinA [15];
[http://blast.ncbi.nlm.nih.gov/Blast.cgi]. Our data on the
origin of the spacers detected in the G. vaginalis CRISPR
arrays propose the hypothesis that the transfer of genetic
material among G. vaginalis strains could be regulated by
the CRISPR/Cas mechanism. Circumstances favourable
for DNA transfer and CRISPR activity would mean the
simultaneous presence of more than one G. vaginalis
strain during infection, which is consistent with previous
reports [21,22,52]. The impact of CRISPR/Cas on the viru-
lence of G. vaginalis could involve the spacer targeting the
GH family 25 gene that encodes a product promoting
competitive exclusion by the 409–05 strain [http://blast.
ncbi.nlm.nih.gov/Blast.cgi].
The distribution of CRISPR/Cas loci among pathogenic
bacteria that incorporate new genetic material, along with
virulence genes, through natural transformation is variable
[27,43]. The incidence of the CRISPR/Cas system among
G. vaginalis strains may be determined by the habitat of
the bacteria. The low prevalence of viruses in the human
endometrium [53] does not promote the acquisition of
CRISPR/Cas by G. vaginalis as an adaptive immunity
Table 1 G. vaginalis CRISPR spacers and known virulence features











ATCC 14019 [15] BV ND + ND + ND 30 24
ATCC 14018 [15] BV 1 - - + ND 30 24
409-05 [15] Asymptomatic BV ND - - + ND 7 7
HMP9231 CP0027525.1 Not known ND + ND + ND - -
101 [14] BV ND + ND + ND - -
41V AEJE01000000.1 Healthy woman ND + ND + ND - -
315A AFDI01000000.1 Not known ND + ND + ND 11 0
5-1 [14] Healthy woman ND - - + ND 6 6
AMD [14] BV ND - - + ND 13 13
284V [22] Abnormal
discharge & odor
1 + ND + ND 2 1
75712 [22] BV 1 + ND + ND 3 2
0288E [22] Abnormal
discharge & odor
1 + ND + ND 3 1
6420LIT [22] Healthy woman 2 - - + ND - -
6420B [22] Healthy woman 2 - - + ND - -
55152 [22] Asymptomatic BV 3 + ND + ND - -
1400E [22] Nugent score 9 4 + ND + ND 1 1
1500E [22] Nugent score 7 5 + ND + ND 5 5
00703Bmash [22] BV 2 or 5 + ND + ND 13 11
00703C2mash [22] BV 2 or 5 + ND + ND 6 3
00703Dmash [22] BV 3 or 7 + ND + ND - -
6119V5 [22] Nugent score 5 7 + ND + ND 8 7
GV15 [18] BV 5 + S + Low - -
GV17 [18] BV 5 + S + Low - -
GV21 [18] BV 1 + W + Medium 11 10
GV22 [18] BV 2 + - + Low 30 13
GV23 [18] BV 1 + W + High - -
GV24 [18] BV 1 + - + Low - -
GV25 [18] BV 1 + W + Low 50 40
GV26 [18] BV 1 + - + Low - -
GV28 [18] BV 5 + S + High 37 25
GV29 [18] BV 1 + - + Low - -
GV30 [18] BV 1 + - + Low 29 27
GV31 [18] BV 1 + W + Medium - -
GV32 [18] BV 1 + - + Medium - -
GV33 [18] BV 5 + S + Low 18 14
GV34 [18] BV 4 + - + Low - -
GV35 [18] BV 5 + S + Low - -
GV36 [18] BV 2 + S + Medium - -
ND – not done.
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is a more favourable environment for virus progression,
and extravaginal reservoirs have an impact on the distribu-
tion of viruses in the vaginal tract [54]. Recent papers have
demonstrated that pathogenic bacteria may lose CRISPR/
Cas under certain selective pressure [55,56]. The presence
of multiple antibiotic resistances is correlated with the loss
of CRISPR loci in enterococci [55]. However, we did
not find a correlation between the presence of CRISPR/
Cas loci and genes responsible for antibiotic/antimicrobial
resistance in G. vaginalis strains. In silico analysis of
G. vaginalis genomes revealed that strains 14018, 14019,
284 V, 315A, 1400E, 0288E, and 00703B, all of which pos-
sessed CRISPR/Cas, contained genes conferring resistance
to bleomycin and methicillin [15]; [http://blast.ncbi.nlm.
nih.gov/Blast.cgi]. In addition, G. vaginalis strains 14018
and 14019 contained a gene coding for an aminoglycoside
phosphotransferase that increased resistance to aminogly-
cosides [15]. Selective pressure for virulence other than
antibiotic resistance might also have an impact on the
presence of CRISPR/Cas loci. In our study, however, the
distribution of CRISPR/Cas systems was variable among
the G. vaginalis strains with elevated virulence potential
that were isolated from BV patients (Table 1). Thus, our
results did not reveal a potential link between the presence
of CRISPR loci and the known virulence features of the
strains (Table 1). Overall, our data suggest that CRISPR-
based typing does not provide a promising tool for epi-
demiological discrimination of G. vaginalis strains. More-
over, G. vaginalis genomic DNA has exhibited such a
great variability [19-22] that the possibility of developing a
routine PCR using a set of specific primers for CRISPR
loci amplification is doubtful.
The fact that the majority of G. vaginalis strains ana-
lysed so far were isolated from symptomatic and asymp-
tomatic BV patients, while only few strains were
obtained from the vaginas of healthy women, could be
an impetus moving forward to elucidate a link between
commensal G. vaginalis strains and CRISPR/Cas loci
(Table 1). Recent findings on the role of Cas proteins in
providing adaptive immunity to bacteria [39,43,57] may
motivate experimental testing of hypotheses on how
CRISPR/Cas impacts the regulation of the transfer of
genetic material among G. vaginalis strains.
The present study is the first attempt to determine and
analyse CRISPR loci in bacteria isolated from the human
vaginal tract. The relationship between prokaryotes and
their environment that is recorded in the spacer sequences
of CRISPR loci sheds light into the genomic evolution of
G. vaginalis.
Conclusions
The CRISPR/Cas system was detected in the genomes of
about one- half of the analysed G. vaginalis strains. Thecas genes in the CRISPR/Cas loci of G. vaginalis belong
to the Ecoli subtype. A total of 285 spacers adjacent to
the cas genes were identified among the 20G. vaginalis
strains containing CRISPR/Cas loci. Approximately 20%
of all of the spacers in the CRISPR arrays had matches
in the GenBank database. Sequence analysis of the
CRISPR arrays revealed that nearly half of the spacers
matched G. vaginalis chromosomal sequences. The spacers
sharing identity with these chromosomal sequences were
determined to not be self-targeting, and presumably were
neither a constituent of mobile-element-associated genes
nor originated from plasmids/viruses. The spacer hits were
mapped to G. vaginalis chromosomal genes, non-coding
regions, or ORF’s encoding hypothetical proteins with
undefined functions. The protospacers located on the G.
vaginalis chromosome display conserved PAMs. We did
not find a link between the presence of CRISPR loci and
the known virulence features of G. vaginalis. Based on the
origin of the spacers found in the G. vaginalis CRISPR
arrays, we hypothesise that the transfer of genetic material
among G. vaginalis strains could be regulated by the
CRISPR/Cas mechanism. Our findings may provide deeper
insights into the genetics of G.vaginalis and promote fur-
ther studies on the role of G. vaginalis in the microbiome
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